Research programme: allergy therapeutics - Actelion

Drug Profile

Research programme: allergy therapeutics - Actelion

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Acetic acids; Acrylamides; Benzimidazoles; Carbazoles
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hypersensitivity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Allergy in Switzerland (PO)
  • 04 Sep 2008 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Hypersensitivity presented at the 20th International Symposium on Medicinal Chemistry (ISMC-2008)
  • 31 Jul 2008 Preclinical trials in Hypersensitivity in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top